Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25814759 | 0.99 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814758 | 0.99 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814681 | 0.99 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814837 | 0.99 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814841 | 0.99 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL19596048 | 0.97 | MAPT (0.33) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814680 | 0.95 | MAPT (0.36) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL17855805 | 0.94 | ALDH1A1 (0.32) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25815304 | 0.94 | PIM3 (0.32) | MAPTSMN1; SMN2KDM4EMEN1LMNA | |
| SCHEMBL17855820 | 0.93 | MAPT (0.32) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225196-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
| US-20230225196-A1 | MATERIALS FOR ELECTRONIC DEVICES | MERCK PATENT GMBH (DE) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225196-A1 | MATERIALS FOR ELECTRONIC DEVICES | SELE, EPHA6, EPX | MAPT 3046/4885SMN1; SMN2 2383/4885ALDH1A1 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.